MedTrace Logo

POF Versus FOLFOX Plus IP Paclitaxel in AGC

NCT04155671 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2019-11-07

No results posted yet for this study

Summary

The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.

Conditions

Interventions

DRUG

POF

Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU

DRUG

FOLFOX plus PAC(ip)

FOLFOX plus intraperitoneally paclitaxel

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2022-11-30
Completion
2023-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04155671 on ClinicalTrials.gov